Shares of AzurRx BioPharma Inc (NASDAQ:AZRX) have received an average recommendation of “Buy” from the six analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $7.50.
AZRX has been the subject of several recent analyst reports. Oppenheimer set a $6.00 target price on shares of AzurRx BioPharma and gave the stock a “buy” rating in a report on Wednesday, December 12th. Maxim Group set a $5.00 target price on shares of AzurRx BioPharma and gave the stock a “buy” rating in a report on Wednesday, February 20th. HC Wainwright set a $8.00 target price on shares of AzurRx BioPharma and gave the stock a “buy” rating in a report on Thursday, December 13th. Roth Capital initiated coverage on shares of AzurRx BioPharma in a report on Friday, January 25th. They issued a “buy” rating and a $10.50 target price for the company. Finally, ValuEngine cut shares of AzurRx BioPharma from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd.
Shares of NASDAQ:AZRX traded up $0.14 during trading hours on Monday, hitting $2.04. 152,662 shares of the company’s stock traded hands, compared to its average volume of 76,946. AzurRx BioPharma has a 52 week low of $1.00 and a 52 week high of $3.75.
In related news, insider Maged Shenouda purchased 20,000 shares of AzurRx BioPharma stock in a transaction dated Friday, December 28th. The stock was acquired at an average cost of $1.31 per share, with a total value of $26,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Johan M. Spoor purchased 38,583 shares of AzurRx BioPharma stock in a transaction dated Friday, December 28th. The stock was bought at an average cost of $1.30 per share, with a total value of $50,157.90. Following the completion of the transaction, the chief executive officer now directly owns 338,617 shares of the company’s stock, valued at $440,202.10. The disclosure for this purchase can be found here. Insiders bought 186,553 shares of company stock valued at $231,349 over the last three months. 7.20% of the stock is owned by insiders.
A hedge fund recently raised its stake in AzurRx BioPharma stock. Vanguard Group Inc lifted its stake in AzurRx BioPharma Inc (NASDAQ:AZRX) by 2.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 413,439 shares of the company’s stock after purchasing an additional 8,489 shares during the quarter. Vanguard Group Inc owned 2.44% of AzurRx BioPharma worth $1,063,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 16.27% of the company’s stock.
About AzurRx BioPharma
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Further Reading: Capital Gains
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.